Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy

NCT07375758 is registered in ClinicalTrials.gov with Beijing Mabworks Biotech Co., Ltd. as lead sponsor.

NCT NCT07375758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07375758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 5, 2026
Completion date
June 30, 2029
Enrollment
130 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunoglobulin a nephropathy